JPRN-UMIN000000692已完成2 期
A phase II/III clinical study of R442(Pegylated Interferon alfa-2a) for patients with chronic hepatitis B. - A phase II/III clinical study of R442(Pegylated Interferon alfa-2a) for patients with chronic hepatitis B.
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 260
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Neutrophil count <1,500 cells/mm3,platelet count < 90,000 cells/mm3, hemoglobin concentration <10 g/dL, hepatitis C co-infection, decompensated liver disease, history of organ transplant, creatinine clearance < 50 mL/min, sever psychiatric disease, diabetes needed pharmacotherapy, poorly controlled hypertention, malignant tumor, severe cardiac or chronic pulmonary disease, immunologically mediated disease, cerebral stroke or retinopathy. Treated by pegylated interferon in the past.
研究者
相似试验
未知
3 期
A phase II/III clinical study of R442 (Pegylated Interferon alfa-2a) for patients with chronic hepatitis B.chronic hepatitis BJPRN-jRCT2080220384Chugai Pharmaceutical Co., Ltd.
未知
2 期
Phase II/III Clinical Study of R484iv (Ibandronic acid) for Primary OsteoporosisOsteoporosisJPRN-jRCT2080220364Chugai Pharmaceutical Co., Ltd. Taisho Pharmaceutical Co., Ltd.
未知
2 期
The Phase II Study of Bardoxolone Methyl in Patients with Chronic Kidney Disease and Type 2 Diabetes; TSUBAKI StudyCKD patients with type 2 diabetesJPRN-jRCT2080222666Kyowa Hakko Kirin Co., Ltd.
未知
2 期
Phase II-III Clinical Study of CSG452(RG7201) in Patients with Type 2 DiabetesType 2 diabetesJPRN-jRCT2080221312Chugai Pharmaceutical Co., Ltd.220
未知
1 期
Phase I of RG3502 in Combination With RG1273HER2 positive Breast CancerJPRN-jRCT2080221197Chugai Pharmaceutical Co., Ltd.6